Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bevra H Hahn

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Arthritis Care & Research|March 2, 2010
Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosusElizabeth R Volkmann, Jennifer M Grossman, Lori J Sahakian, et al.
Annals of the Rheumatic Diseases|July 7, 2022
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosusRonald F van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, et al.
Arthritis and Rheumatism|August 1, 2009
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosusMaureen McMahon, Jennifer Grossman, Brian Skaggs, et al.
Lancet (London, England)|September 26, 2018
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled studyRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Arthritis Research & Therapy|January 25, 2013
Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosusOrnella J Rullo, Jennifer M P Woo, Miriam F Parsa, et al.
Annals of the Rheumatic Diseases|June 15, 2011
High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipidsMaureen McMahon, Brian J Skaggs, Lori Sahakian, et al.
Medical Care|February 7, 2007
The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease careKatherine L Kahn, Catherine H MacLean, Honghu Liu, et al.
Arthritis and Rheumatism|November 13, 2002
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosusBetty P Tsao, Rita M Cantor, Jennifer M Grossman, et al.
Arthritis and Rheumatism|October 18, 2002
Familiality and co-occurrence of clinical features of systemic lupus erythematosusBetty P Tsao, Jennifer M Grossman, Gabriela Riemekasten, et al.
Arthritis and Rheumatism|September 2, 2006
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosusXuebing Feng, Hui Wu, Jennifer M Grossman, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Arthritis Care & Research|March 2, 2010
Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosusElizabeth R Volkmann, Jennifer M Grossman, Lori J Sahakian, et al.
Annals of the Rheumatic Diseases|July 7, 2022
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosusRonald F van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, et al.
Arthritis and Rheumatism|August 1, 2009
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosusMaureen McMahon, Jennifer Grossman, Brian Skaggs, et al.
Lancet (London, England)|September 26, 2018
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled studyRonald F van Vollenhoven, Bevra H Hahn, George C Tsokos, et al.
Arthritis Research & Therapy|January 25, 2013
Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosusOrnella J Rullo, Jennifer M P Woo, Miriam F Parsa, et al.
Annals of the Rheumatic Diseases|June 15, 2011
High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipidsMaureen McMahon, Brian J Skaggs, Lori Sahakian, et al.
Medical Care|February 7, 2007
The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease careKatherine L Kahn, Catherine H MacLean, Honghu Liu, et al.
Arthritis and Rheumatism|November 13, 2002
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosusBetty P Tsao, Rita M Cantor, Jennifer M Grossman, et al.
Arthritis and Rheumatism|October 18, 2002
Familiality and co-occurrence of clinical features of systemic lupus erythematosusBetty P Tsao, Jennifer M Grossman, Gabriela Riemekasten, et al.
Arthritis and Rheumatism|September 2, 2006
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosusXuebing Feng, Hui Wu, Jennifer M Grossman, et al.
Pageof 10